Company Profile
Eledon Pharmaceuticals, Inc. Stock Price, News & Analysis
- Ticker:
- ELDN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.46 USD (+0.58%)
Close
Last updated: August 6, 2026
272M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, ELDN closed up 0.58% at $3.46. No new same-company headline was identified in the current news window.
Company overview
Transplant Immunology Company
Eledon Pharmaceuticals develops therapies intended to protect transplanted organs and cells while reducing reliance on broadly immunosuppressive regimens.
Tegoprubart
Tegoprubart is an anti-CD40L antibody designed to block a central co-stimulatory pathway involved in transplant rejection while preserving other immune functions.
Kidney and Islet Transplantation
Clinical programs include kidney transplantation and an investigator-led islet-cell transplant study in people with high-risk type 1 diabetes, where insulin independence has been observed.
Broader Organ Transplantation
FDA Orphan Drug designation in liver transplantation adds another potential setting for tegoprubart beyond kidney and islet-cell replacement.
Future catalysts
Eledon’s catalysts are tegoprubart and the immunology / transplant pipeline, where the next update can materially move the stock. The company still needs stronger human proof.
Recent news
- 01
- 02
- 03
- 04
- 05
Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights
Source: Eledon Pharmaceuticals, Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Eledon Pharmaceuticals, Inc. (ELDN)?
Eledon Pharmaceuticals, Inc. (ELDN) most recently closed at 3.46 USD, a +0.58% move versus the previous session.
What is the market cap of Eledon Pharmaceuticals, Inc. (ELDN)?
Eledon Pharmaceuticals, Inc. currently has a market capitalization of 272M USD on BioPharmSignal.
What does Eledon Pharmaceuticals, Inc. do?
Transplant Immunology Company Eledon Pharmaceuticals develops therapies intended to protect transplanted organs and cells while reducing reliance on broadly immunosuppressive regimens. Tegoprubart Tegoprubart is an anti-CD40L antibody designed to block a central co-stimulatory pathway involved in transplant rejection while preserving other immune...
On which exchange is ELDN stock listed?
Eledon Pharmaceuticals, Inc. (ELDN) is associated with NASDAQ, United States, Biopharma.
What is Transplant?
Eledon’s catalysts are tegoprubart and the immunology / transplant pipeline, where the next update can materially move the stock.
Which conditions is Eledon Pharmaceuticals, Inc. targeting with Transplant?
Eledon Pharmaceuticals, Inc. is associated with immunology, diabetes based on its company overview and current catalyst commentary.
How does Eledon Pharmaceuticals, Inc. describe recent progress with Transplant?
Eledon’s catalysts are tegoprubart and the immunology / transplant pipeline, where the next update can materially move the stock.
What is Immunology?
Transplant Immunology Company Eledon Pharmaceuticals develops therapies intended to protect transplanted organs and cells while reducing reliance on broadly immunosuppressive regimens.